Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in ...
New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.
Hosted on MSN1mon
Samsung Biologics inks $668m manufacturing deal with European pharmaIn July 2024, Samsung Bioepis received US Food and Drug Administration (FDA) approval for Epysqli (eculizumab-aagh), a biosimilar to AstraZeneca acquiree Alexion Pharmaceuticals’ Soliris ...
South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, development and commercialization agreement for Epysqli (eculizumab-aagh), ...
INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback